Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Young-Sun | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Kim, Ji Hoon | - |
dc.contributor.author | Lee, Juneyoung | - |
dc.contributor.author | Kim, Hae Rim | - |
dc.contributor.author | Yoo, Yang Jae | - |
dc.contributor.author | Kim, Tae Suk | - |
dc.contributor.author | Kang, Seong Hee | - |
dc.contributor.author | Suh, Sang Jun | - |
dc.contributor.author | Joo, Moon Kyung | - |
dc.contributor.author | Jung, Young Kul | - |
dc.contributor.author | Lee, Beom Jae | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Yeon, Jong Eun | - |
dc.contributor.author | Kim, Jae Seon | - |
dc.contributor.author | Park, Jong-Jae | - |
dc.contributor.author | Um, Soon Ho | - |
dc.contributor.author | Bak, Young-Tae | - |
dc.contributor.author | Byun, Kwan Soo | - |
dc.date.accessioned | 2021-09-02T17:06:23Z | - |
dc.date.available | 2021-09-02T17:06:23Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2018-01 | - |
dc.identifier.issn | 1976-2283 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/78476 | - |
dc.description.abstract | Background/Aims: In addition to the globally endorsed Barcelona Clinic Liver Cancer (BCLC) staging system, other algorithms or staging systems have been developed, including the Hong Kong Liver Cancer (HKLC) staging system. This study aimed to validate the HKLC staging system relative to the BCLC staging system for predicting survival for hepatocellular carcinoma (HCC) patients in Korea. Methods: From 2004 to 2013, 2,571 patients newly diagnosed with HCC were consecutively enrolled at three Korea University medical centers. Results: Both staging systems differentiated survival well (p<0.001). However, 1-year and 3-year survival were predicted better using the HKLC system than the BCLC system (area under the receiver operating characteristic curve: 0.869 vs 0.856 for 1 year, p=0.002; 0.841 vs 0.827 for 3 years, p=0.010). In hypothetical survival curves, the HKLC system exhibited better median overall survival than the BCLC system (33.1 months vs 19.2 months). In evaluations of prognosis according to either BCLC or HKLC treatment guidelines, risk of death was reduced in the group following only HKLC guidelines compared with the group following only BCLC guidelines (hazard ratio, 0.601; 95% confidence interval, 0.443 to 0.816; p=0.001). Conclusions: Although both staging systems predicted and discriminated HCC prognoses well, the HKLC system showed more encouraging survival benefits than the BCLC system. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | EDITORIAL OFFICE GUT & LIVER | - |
dc.subject | STAGING SYSTEM | - |
dc.subject | TRANSARTERIAL CHEMOEMBOLIZATION | - |
dc.subject | STRATIFICATION | - |
dc.subject | HETEROGENEITY | - |
dc.subject | PERFORMANCE | - |
dc.subject | VALIDATION | - |
dc.subject | MANAGEMENT | - |
dc.subject | CIRRHOSIS | - |
dc.subject | RESECTION | - |
dc.subject | PATTERNS | - |
dc.title | Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Young-Sun | - |
dc.contributor.affiliatedAuthor | Seo, Yeon Seok | - |
dc.contributor.affiliatedAuthor | Kim, Ji Hoon | - |
dc.contributor.affiliatedAuthor | Lee, Juneyoung | - |
dc.contributor.affiliatedAuthor | Joo, Moon Kyung | - |
dc.contributor.affiliatedAuthor | Jung, Young Kul | - |
dc.contributor.affiliatedAuthor | Lee, Beom Jae | - |
dc.contributor.affiliatedAuthor | Yim, Hyung Joon | - |
dc.contributor.affiliatedAuthor | Yeon, Jong Eun | - |
dc.contributor.affiliatedAuthor | Kim, Jae Seon | - |
dc.contributor.affiliatedAuthor | Park, Jong-Jae | - |
dc.contributor.affiliatedAuthor | Um, Soon Ho | - |
dc.contributor.affiliatedAuthor | Bak, Young-Tae | - |
dc.contributor.affiliatedAuthor | Byun, Kwan Soo | - |
dc.identifier.doi | 10.5009/gnl17040 | - |
dc.identifier.scopusid | 2-s2.0-85040517115 | - |
dc.identifier.wosid | 000423401300015 | - |
dc.identifier.bibliographicCitation | GUT AND LIVER, v.12, no.1, pp.94 - 101 | - |
dc.relation.isPartOf | GUT AND LIVER | - |
dc.citation.title | GUT AND LIVER | - |
dc.citation.volume | 12 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 94 | - |
dc.citation.endPage | 101 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002310649 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | STAGING SYSTEM | - |
dc.subject.keywordPlus | TRANSARTERIAL CHEMOEMBOLIZATION | - |
dc.subject.keywordPlus | STRATIFICATION | - |
dc.subject.keywordPlus | HETEROGENEITY | - |
dc.subject.keywordPlus | PERFORMANCE | - |
dc.subject.keywordPlus | VALIDATION | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | CIRRHOSIS | - |
dc.subject.keywordPlus | RESECTION | - |
dc.subject.keywordPlus | PATTERNS | - |
dc.subject.keywordAuthor | Carcinoma | - |
dc.subject.keywordAuthor | hepatocellular | - |
dc.subject.keywordAuthor | Barcelona Clinic Liver Cancer | - |
dc.subject.keywordAuthor | Hong Kong Liver Cancer | - |
dc.subject.keywordAuthor | Neoplasm staging | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.